RVX is somewhat short of capital...they are trying to dilute as little as they can before Phase 3 top line results are out.  

The longer the trial takes, the better the chances of Apabetalone working...but it also means that RVX's need for fresh capital keeps growing.  The next raise will be just enough to keep the Third Eye loan convenants in line, and pay for cash burn for a few more months.  The raise will most likely take place at the last price of $3 or so.  Raising that capital won't be an issue.  But if the trial ends earlier, then that is not so great...at least on the margin.  

That is why the volumes are drying up and the price won't go below $3.